Search

Your search keyword '"´Adrián Daneri-Navarro"' showing total 9 results
Start Over Author "´Adrián Daneri-Navarro"
9 results on '"´Adrián Daneri-Navarro"'

1. Implementing Standard Diagnosis and Treatment for Locally Advanced Breast Cancer Through Global Research in Latin America: Results From a Multicountry Pragmatic Trial

Author

Javier Retamales, Adrián Daneri-Navarro, Nora Artagaveytia, Daniela Alves da Quinta, Eliana Abdelhay, Osvaldo L. Podhajcer, Carlos Velázquez, Diego Giunta, Susanne Crocamo, Adriana Garibay-Escobar, Alicia Del Toro-Arreola, Robinson Rodriguez, Marta Aghazarian, Elsa Alcoba, Isabel Alonso, Renata Binato, Alicia I. Bravo, Juan Canton-Romero, Dirce M. Carraro, Mónica Castro, Juan Castro-Cervantes, Sandra Cataldi, Natalia Camejo, Laura Cortes-Sanabria, Maria Flores-Marquez, Guillermo Laviña, Eduardo Musetti, Benedicta Caserta, Mauricio Cerda, Alicia Colombo, Raul Delgadillo-Cristerna, Marisa Dreyer Breitenbach, Elmer Fernandez, Jorge Fernandez, Ramon Franco-Topete, Carolina Gabay, Fancy Gaete, Jorge Gamboa, Ricardo García-Gaeta, Mariana Gomez del Toro, Leivy P. Gonzalez-Ramirez, Marisol Guerrero, Manuel Herrera-Miramontes, Alejandra Lopez-Vasquez, Silvina Maldonado, Andrés Morán-Mendoza, Gilberto Morgan-Villela, Maria Aparecida Nagai, Nancy Navarro-Ruiz, Antonio Oceguera-Villanueva, Miguel Angel Ortiz, Jael Quintero, Antonio Quintero-Ramos, Gladys Ramirez-Rosales, Maritza Ramos-Ramirez, Marcia Maria Chiquitelli Marques, Ernesto Rivera Claisse, Diego Rodriguez-Gonzalez, Ana Romero-Gomez, Cristina Rosales, Efraín Salas-Gonzalez, Verónica Sanchotena, Laura Segovia, Aída A. Silva-García, Olivia Valenzuela-Antelo, Laura Venegas-Godinez, Livia Zagame, Jorge Gomez, Andrea S. Llera, and Bettina Müller

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

PURPOSEBreast cancer mortality rates in Latin America (LA) are higher than those in the United States, possibly because of advanced disease presentation, health care disparities, or unfavorable molecular subtypes. The Latin American Cancer Research Network was established to address these challenges and to promote collaborative clinical research. The Molecular Profiling of Breast Cancer Study (MPBCS) aimed to evaluate the clinical characteristics and treatment outcomes of LA participants with locally advanced breast cancer (LABC).PATIENTS AND METHODSThe MPBCS enrolled 1,449 participants from Argentina, Brazil, Chile, Mexico, and Uruguay. Through harmonized procedures and quality assurance measures, this study evaluated clinicopathologic characteristics, neoadjuvant chemotherapy response, and survival outcomes according to residual cancer burden (RCB) and the type of surgery.RESULTSOverall, 711 and 480 participants in the primary surgery and neoadjuvant arms, respectively, completed the 5-year follow-up period. Overall survival was independently associated with RCB (worse survival for RCBIII-adjusted hazard ratio, 8.19, P < .001, and RCBII [adjusted hazard ratio, 3.69, P < .008] compared with RCB0 [pathologic complete response or pCR]) and type of surgery (worse survival in mastectomy than in breast-conserving surgery [BCS], adjusted hazard ratio, 2.97, P = .001). The hormone receptor–negative-human epidermal growth factor receptor 2–positive group had the highest proportion of pCR (48.9%). The analysis of the ASCO Quality Oncology Practice Initiative breast module revealed high compliance with pathologic standards but lower adherence to treatment administration standards. Notably, compliance with trastuzumab administration varied widely among countries (33.3%-88.7%).CONCLUSIONIn LABC, we demonstrated the survival benefit of BCS and the prognostic effect of the response to available neoadjuvant treatments despite an important variability in access to key treatments. The MPBCS represents a significant step forward in understanding the real-world implementation of oncologic procedures in LA.

Published
2024
Full Text
View/download PDF

2. HLA-G 14 bp Ins/Del (rs66554220) Variant Is Not Associated with Breast Cancer in Women from Western Mexico

Author

Denisse Stephania Becerra-Loaiza, Luisa Fernanda Roldan Flores, Luis Antonio Ochoa-Ramírez, Bricia M. Gutiérrez-Zepeda, Alicia Del Toro-Arreola, Ramón Antonio Franco-Topete, Andrés Morán-Mendoza, Antonio Oceguera-Villanueva, Antonio Topete, David Javalera, Antonio Quintero-Ramos, and Adrián Daneri-Navarro

Subjects
breast cancer, HLA-G, Mexican population, rs66554220, 14-bp Ins/Del, western Mexico, Biology (General), QH301-705.5
Abstract

HLA-G is a physiology and pathologic immunomodulator detrimentally related to cancer. Its gene is heavily transcriptionally and post-transcriptionally regulated by variants located in regulator regions like 3′UTR, being the most studied Ins/Del of 14-bp (rs66554220), which is known to influence the effects of endogen cell factors; nevertheless, the reports are discrepant and controversial. Herein, the relationship of the 14-bp Ins/Del variant (rs66554220) with breast cancer (BC) and its clinical characteristics were analyzed in 182 women with non-familial BC and 221 disease-free women as a reference group. Both groups from western Mexico and sex–age-matched (sm-RG). The rs66554220 variant was amplified by SSP-PCR and the fragments were visualized in polyacrylamide gel electrophoresis. The variant rs66554220 was not associated with BC in our population. However, we suggest the Ins allele as a possible risk factor for developing BC at clinical stage IV (OR = 3.05, 95% CI = 1.16–7.96, p = 0.01); nevertheless, given the small stratified sample size (n = 11, statistical power = 41%), this is inconclusive. In conclusion, the 14-bp Ins/Del (rs66554220) variant of HLA-G is not associated with BC in the Mexican population, but might be related to advanced breast tumors. Further studies are required.

Published
2023
Full Text
View/download PDF

3. The Transcriptomic Portrait of Locally Advanced Breast Cancer and Its Prognostic Value in a Multi-Country Cohort of Latin American Patients

Author

Andrea Sabina Llera, Eliana Saul Furquim Werneck Abdelhay, Nora Artagaveytia, Adrián Daneri-Navarro, Bettina Müller, Carlos Velazquez, Elsa B. Alcoba, Isabel Alonso, Daniela B. Alves da Quinta, Renata Binato, Alicia Inés Bravo, Natalia Camejo, Dirce Maria Carraro, Mónica Castro, Juan M. Castro-Cervantes, Sandra Cataldi, Alfonso Cayota, Mauricio Cerda, Alicia Colombo, Susanne Crocamo, Alicia Del Toro-Arreola, Raúl Delgadillo-Cisterna, Lucía Delgado, Marisa Dreyer-Breitenbach, Laura Fejerman, Elmer A. Fernández, Jorge Fernández, Wanda Fernández, Ramón A. Franco-Topete, Carolina Gabay, Fancy Gaete, Adriana Garibay-Escobar, Jorge Gómez, Gonzalo Greif, Thomas G. Gross, Marisol Guerrero, Marianne K. Henderson, Miguel E. Lopez-Muñoz, Alejandra Lopez-Vazquez, Silvina Maldonado, Andrés J. Morán-Mendoza, Maria Aparecida Nagai, Antonio Oceguera-Villanueva, Miguel A. Ortiz-Martínez, Jael Quintero, Antonio Quintero-Ramos, Rui M. Reis, Javier Retamales, Ernesto Rivera-Claisse, Darío Rocha, Robinson Rodríguez, Cristina Rosales, Efrain Salas-González, Verónica Sanchotena, Laura Segovia, Juan Martín Sendoya, Aida A. Silva-García, Alejandra Trinchero, Olivia Valenzuela, Vidya Vedham, Livia Zagame, United States-Latin American Cancer Research Network (US-LACRN), Osvaldo L. Podhajcer, Juan Abarca, Pamela Acevedo, Graciela Acosta, Gissel Acosta, Gabriela Acosta Haab, Ana Lilian Acosta Silva, Marta Aghazarian, Carola Aguayo, Bernardo Aizen, Gustavo Alarcon Lopez, Liz Almeida, Ana Alvarez, Viviane Andrade, Wenceslao Angeles-Bueno, Roberto Arai, Priscila Elvira Arambula Barreras, Ma. Isabel Aramburo Rubio, Gonzalo Ardao, Lilia A. Arellano-Jimenez, Claudia Arias, Ricardo Armisen, Mauricio Aspee, Rodrigo Assar, Itzel Reneé Astiazarán Rascón, Sebastian Astorga, Maxwell Aviles Rodriguez, Antônio Bailão Junior, Adolfo E. Barragan-Curiel, Adelfo Barragan-Ruiz, Fernanda Bermudez, Julia Bernachin, Wilfrido Bernal Herrera, Mara Bonet, Sarah Brnich, Claudio Bustamante, Miguel Angel Bustamante, Julio Bustos-Gomez, Felipe de J Bustos-Rodriguez, Janett Caballero Jasso, Angie Calfuman, Antonio Hugo José Froes Marques, Mónica Campos, Soledad Cano, Juan C. Canton-Romero, Ricardo Cappetta, Paulina Carmona, Fernando Carrizo, André Lopes Carvalho, Erika Carvallo, Julio Carzoglio, Monica Casalnuovo, Benedicta Caserta, Alvaro Castillo, César Castillo, Roger Chammas, Mario Alberto Chavez Zamudio, Loreto Chia, Elisa Chiarello, Daniela Chirico, Esther Cisneros-Quirarter, Minor Raul Cordero Bautista, Valeria Cornejo, Baldemar Corral Villegas, Andrés Cortés, Sandra Cortés, Laura Cortes-Sanabria, German Salvador Cortez Zamorano, Alejandro Corvalan, Adolfo Cruz, Alba d'Aurora, Sandra De la Fuente, Soledad De la Peña, Roberto de Leon Caballero, Mirian de Souza, César Del Castillo, Azucena Del-Toro-Valero, Mirtha Di Pretoro, Andrea Digonzelli, Jose El Ters, Paula Escobar, Marcela Estolaza, Adriane Feijo Evangelista, Marcelo Fanelli, Paulo Farias, Graciela Fernandez, José R. Filassi, Natalia Filgueiras, Diego Flaks, Edgar G. Flores-Ayala, Maria R. Flores-Marquez, David Franco Hughes, Karina Franco-Topete, Jimena Freire, Cristobal Fresno, Romina Gabrielli, Mario Gallegos, Jorge Gamboa, Daiana Ganiewich, Carlos Garbovesky, Ruben Alejandro Garcia Munguia, Ricardo Garcia-Gaeta, Alma C. Garcia-Martinez, Liliana Gimenez, Hector Gómez Silveira, Mariana M. Gomez-Del Toro, Marcela Gonzalez, Alicia Gonzalez, Germán González, Cesar Osbaldo Gonzalez Mondaca, Leivy P. Gonzalez-Ramirez, Beatriz Gonzalez-Ulloa, Susana Gorostidy, Mariela Grass, Alfonso G. Guevara Torres, Lorena Gutierrez, Susan A. Gutierrez-Rubio, Adrián Hannois, Andrew Hart, Steffen Härtel, Marcos Henriquez, Rafael Hernandez Guevara, Miriam E. Hernandez-Franco, Manuel I. Herrera-Miramontes, Graciela Horton, Gladys Ibañez, Martín Ipiña, Beatriz Jalfin, Lilian Jara, Raul Jara, Maria Luisa Jaramillo, David Javalera-Castro, Maria Eugenia Jimenez, Hugo Ju, Nazareth Juárez Rusjan, Karen Juneman, Ligia Maria Kerr, Alejandra Krupelis, Flor Esmeralda Larios-Jimenez, Jose Domingo Latorre, Guillermo Laviña, Fernando Lavista, Irma Leticia León Duarte, Alberto Lescano, Verónica Lezano, Rossana Mendoza Lopez, Jose Guillermo Lopez Cervantes, Miguel Enrique Lopez Muñoz, Dora Loria, Alejandra Luque, Alejandro Maass, Maria do Socorro Maciel, Flavia Rotea Mangone, Jorge Mansilla, Katherine Marcelain, Carolina Mariani, Marcia Maria Chiquitelli Marques, Reyna J. Martinez-Arriaga, Hector R. Martinez-Ramirez, Marcela Martins, Alma G. Maya-Gonzalez, Brenda Mazzaferri, Yadira Medina-Mora, Mariana Menini, Silvia Míguez, Soledad Milans, Soledad Montes, Ana Verónica Morales Hernández, Giberto Morga-Villela, Carla Morong, Homero Muñoz, Ignacio Miguel Muse, Carina Mussetti, Eduardo Mussetti, Luis J. Najar-Acosta, Elisa Napolitano e Ferreira, Nancy E. Navarro-Ruiz, Cristina Noblía, João Soares Nunes, Daniela Núñez, Fabiola Núñez, Nilton Onari, Emma M. Oropeza-De Anda, David Ortega Tirado, Cynthia Aparecida Bueno de Toledo Osório, Carlos Eduardo Paiva, Paulina Peñaloza, Miguel Peredo-Navarro, David Pereira, Laura Perez Michel, Francisca Pino, Tania Pino, Natalia Pinto, Jessica Pizarro, Carlos Pressa, Enrique Ramirez, Gladys E. Ramirez-Rosales, Claudia Ramis, Maritza Ramos-Ramirez, Adela Rascon Alcantar, Silvana Ravaglio, Francois Richard, Omar Rios Méndez, Ramón Enrique Robles Zepeda, Iara Santana Rocha, Natalia Rodriguez, Vilma Rodriguez, Maria Teresa Rodriguez, Diego Rodriguez-Gonzalez, Rosemeire A Roela, Ana M Romero-Gomez, Ana M Rosales-Sandoval, Omar V Rubio-Plascencia, Florencia Russo, Gaciela Sabini, Isabel Saffie, Helena Salina Dias, Brenda Guadalupe Samaniego Soto, Julio San Martino, Benito Sanchez-Llamas, Daniel Sat-Muñoz, Mariana Savignano, Cristovam Scapulatempo Neto, Max Mano Senna, Carolina Silva, Jaime Silvera, Isabele Small, Fernando Soares, Iberê Soares, Silvana Soares dos Santos, Evandro Sobrosa de Mello, José Antonio Sola, Irene Sorín, Alejandra Sosa, Anabella Sosa, Claudio Sosa, Sandra Soto, Cristiano de Pádua Souza, Lucía Spangenberg, Gustavo Steffanof, Florencia Straminsky, Mónica Tapia, Raziel O. Tapia-Llanos, Geronimo M. Tavares-Macias, Guillermo Temperley, Veronica Terzieff, Vicente Teti, Javier Tognarelli, Verónica Toledo, Paulina Toro, Roberto Torres, Mariana Torres-Palomares, Rogelio Troyo-San Roman, Hernan Urbano, Nicolas Vacca, Daniel Vaimberg, María Lourdes Valencia Peña, Maria Lujan Vaselevich, Jaime Vazquez-Nares, Ezequiel Velez-Gomez, Laura N. Venegas-Godinez, Patricia Vercelli, Ricardo Verdugo, René Aloisio da Costa Vieira, Marta Vilensky, María José Villarubias, Manuel Isaac Villegas Gómez, Stella Viña, Silvia Vornetti, Anapaula Hidemi Uema Watanabe, Carlos Zamorano, Luis Zapata, and Zdenka Zlatar

Subjects
breast cancer, Latin America, PAM50 subtypes, risk of recurrence, biological pathways, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

PurposesMost molecular-based published studies on breast cancer do not adequately represent the unique and diverse genetic admixture of the Latin American population. Searching for similarities and differences in molecular pathways associated with these tumors and evaluating its impact on prognosis may help to select better therapeutic approaches.Patients and MethodsWe collected clinical, pathological, and transcriptomic data of a multi-country Latin American cohort of 1,071 stage II-III breast cancer patients of the Molecular Profile of Breast Cancer Study (MPBCS) cohort. The 5-year prognostic ability of intrinsic (transcriptomic-based) PAM50 and immunohistochemical classifications, both at the cancer-specific (OSC) and disease-free survival (DFS) stages, was compared. Pathway analyses (GSEA, GSVA and MetaCore) were performed to explore differences among intrinsic subtypes.ResultsPAM50 classification of the MPBCS cohort defined 42·6% of tumors as LumA, 21·3% as LumB, 13·3% as HER2E and 16·6% as Basal. Both OSC and DFS for LumA tumors were significantly better than for other subtypes, while Basal tumors had the worst prognosis. While the prognostic power of traditional subtypes calculated with hormone receptors (HR), HER2 and Ki67 determinations showed an acceptable performance, PAM50-derived risk of recurrence best discriminated low, intermediate and high-risk groups. Transcriptomic pathway analysis showed high proliferation (i.e. cell cycle control and DNA damage repair) associated with LumB, HER2E and Basal tumors, and a strong dependency on the estrogen pathway for LumA. Terms related to both innate and adaptive immune responses were seen predominantly upregulated in Basal tumors, and, to a lesser extent, in HER2E, with respect to LumA and B tumors.ConclusionsThis is the first study that assesses molecular features at the transcriptomic level in a multicountry Latin American breast cancer patient cohort. Hormone-related and proliferation pathways that predominate in PAM50 and other breast cancer molecular classifications are also the main tumor-driving mechanisms in this cohort and have prognostic power. The immune-related features seen in the most aggressive subtypes may pave the way for therapeutic approaches not yet disseminated in Latin America.Clinical Trial RegistrationClinicalTrials.gov (Identifier: NCT02326857).

Published
2022
Full Text
View/download PDF

4. Adaptación y evaluación de la eficacia de un programa psicoeducativo de navegación para disminuir síntomas de ansiedad y depresión en mujeres mexicanas con cáncer de mama

Author

Flor E. Larios-Jiménez, Leivy P. González-Ramírez, Sara K. Rivas-Medina, Antonio Oceguera-Villanueva, Adelfo Barragán-Ruíz, Andrés de J. Morán-Mendoza, Juan M. Castro-Cervantes, Pedro Solano-Murillo, Gilberto Morgan-Villela, Mónica Montero-Ramírez, Fabiola González- Betanzos, Roberto Montes-Delgado, Rebeca Robles-García, and ´Adrián Daneri-Navarro

Subjects
Clinical Psychology, Oncology
Abstract

Objetivo: El cáncer de mama (CAM) es un problema de salud pública mundial. La ansiedad y depresión son las principales comorbilidades que aquejan a este sector, el programa psicoeducativo de navegación (PPN) se presenta como una estrategia psicosocial eficaz en hospitales públicos de México. Método: Se realizó la adaptación del PPN y la evaluación de eficacia en 47 mujeres con CAM de tres hospitales de la Zona Metropolitana de Guadalajara. El PPN integró acompañamiento emocional, educación para la salud y técnicas de relajación. Se evaluaron los síntomas y los niveles de ansiedad y depresión, pre-post intervención con la Escala Hospitalaria de Ansiedad y Depresión (HADS). Resultados: Se encontró una disminución en los síntomas de ansiedad pre-test (M= 6,79, DT= 4,01) y pos-test (M= 4,19, DT= 3,03), igual que en los síntomas de depresión antes (M= 6,02, DT= 4,07) y después (M= 4,23, DT= 3,05). Se obtuvieron diferencias estadísticamente significativas entre las evaluaciones pre y post intervención tanto en las dimensiones, como en la puntuación global (p

Published
2023
Full Text
View/download PDF

5. Evaluation of psychosocial aspects in participants of cancer genetic counseling

Author

Leivy Patricia González-Ramírez, Reyna Martínez-Arriaga, Erendira Camacho-Cárdenas, Azucena Del Toro-Valero, Antonio Oceguera-Villanueva, Livia Zagamé, Aída Araceli Silva-García, and Adrián Daneri-Navarro

Subjects
Cancer genetic counseling, Breast cancer, Anxiety, Depression scale, Psychological Health Interview, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282, Genetics, QH426-470
Abstract

Abstract Background The instrument called “Hospital Anxiety and Depression Scale” (HADS) is frequently used to evaluate anxious and depressive symptomatology in patients who receive Cancer Genetic Counseling (CGC). However, this instrument cannot identify all of the psychosocial factors, such as the antecedents of the patients’ emotional states or their concerns. The objective of the present research was to compare cases detected with psychosocial alterations by means of HADS and a Psychological Health Interview (PHI). Methods A transversal analytical design was used. One hundred ten participants were included (97.3% females and 2.7% males). The average age was 45 years ±10 years. Results The PHI identified twice the amount of participants with psychosocial alterations than did HADS, which only detected 43% of these participants. Conclusions The results of our study suggest that the PHI should be applied in addition to HADS to identify participants who would require psychological support due to recurrent concerns.

Published
2017
Full Text
View/download PDF

7. List of contributors

Author

Pavan Kumar Achalla, Geeta Aggarwal, Mohammad Sarwar Alam, Ron R. Allison, Waleed H. Almalki, Ravi Bandaru, Hellen Franciane Gonçalves Barbosa, Alexandra Yu. Belik, Ishita Chakraborty, Özlem Çoban, Thomas Dandekar, Rambabu Dandela, Adrián Daneri-Navarro, Camila Fabiano de Freitas, Willian Max O.S. de Santana, Anuradha Dey, Sunil Kumar Dubey, Mahmut Durmuş, Noé Escareño, Carla Raquel Fontana, Marcus Frohme, Anna Grebinyk, Sergii Grebinyk, Sıla Gülbağ Pinar, Nazeer Hasan, Mohammad Irani, Gaurav K. Jain, Gowtham Kenguva, Prashant Kesharwani, Alexander I. Kotelnikov, Alexei V. Kozlov, Piyush Kumar, Kriengsak Lirdprapamongkol, Olga Matyshevska, Nirmal Mazumder, Keyvan Moghissi, Sadra Mohammad, Thokur Sreepathy Murali, İpek Ömeroğlu, Dilek Öztürk, Shraddha Parab, Diogo Silva Pellosi, Daniel José Pochapski, Sasivimon Pramual, Svitlana Prylutska, Yuriy Prylutskyy, Sandra H. Pulcinelli, Anu Puri, Uwe Ritter, Smruti Rekha Rout, Alexander Yu. Rybkin, Celso V. Santilli, Kapaettu Satyamoorthy, Dinesh Sharma, Samin Sheikholeslami, Rahul Shukla, Sima Singh, Gautam Singhvi, Jisnuson Svasti, Afsaneh Tavasoli, Antonio Claudio Tedesco, André Luiz Tessaro, Antonio Topete, Adrián A. Villanueva-Briseño, Anjali Warrier, Nitheesh Yanamandala, and Duygu Yilmaz Usta

Published
2023
Full Text
View/download PDF

8. [Lymphocyte subsets and preeclampsia]

Author

Luz Ma Adriana, Balderas Peña, Carlos Vidal, Vizcaíno Magaña, Salvador, Hernández Higareda, Cecilia, Vargas Guillén, Fernando, Alvarez Romo, Trinidad, García Iglesias, Susana, del Toro Arreola, and Adrián, Daneri Navarro

Subjects
Adult, Pre-Eclampsia, Pregnancy, Humans, Female, Lymphocyte Count, Lymphocyte Subsets
Abstract

Preeclampsia origin has no conclusive explanation. As part of its etiology it has been proposed immunologic disorders. This work explores several lymphocytes subsets and postulates possible mechanisms involved in a lost of immune tolerance in this entity.To compare cellular populations of CD3+ CD56+, CD4+ CD25+, T lymphocytes (CD4+ and CD8+) and NK cells subsets in preeclamptic and pregnant healthy women.Through flow cytometry antibodies, peripheral blood mononuclear cells were obtained from both groups of patients. CD3+ CD56+, CD4+ CD25+, T lymphocytes (CD4+ and CD8+) and NK cells were identified. Mean and standard deviation, Student ttest and Pearson correlation were calculated to analyze differences between groups and correlation between mean blood pressure and different lymphocytes subsets; p0.05 was considered significant.CD3+ CD56+ cells percentage was lower in preeclamptic patients (2.7 vs 6.1%; p0.002), CD4+ CD25+ cells percentage tend to be lower too (22.11 vs 33.86; p = NS). Mean blood pressure shown negative correlation with CD3+ CD56+ cells percentage (rp - 0.666; p = 0.001) and with CD25 on CD4+ T lymphocytes surface (rp - 0.526; p0.025).Based on the association between mean blood pressure and lymphocytes percentage for these two cellular subsets, data obtained suggest that CD3+ CD56+ and CD4+ CD25+ cells play an important role in preeclampsia development.

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results